AstraZeneca Restructures Biopharm Business to Strengthen Autoimmune and Respiratory Therapies
UK-based AstraZeneca’s (AZ, NASDAQ: AZN) Biopharmaceuticals Business Unit (BBU), established last year, is undergoing a...
AstraZeneca
AstraZeneca to Invest $50 Billion in US Manufacturing and R&D Expansion by 2030
UK-based AstraZeneca (AZ, NASDAQ: AZN) announced plans to invest $50 billion in the United States by...
AstraZeneca’s FLAURA2 Study Confirms Osimertinib Combo’s Survival Benefit in NSCLC
UK-based AstraZeneca (AZ, NASDAQ: AZN) announced the final overall survival (OS) results from the Phase III...
Daiichi Sankyo and AstraZeneca Submit Enhertu Application for HER2-Positive Gastric Cancer in China
Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) have submitted a supplemental new-drug application...
AstraZeneca’s Baxdrostat Meets Primary and Secondary Endpoints in Phase III BaxHTN Trial
UK-based AstraZeneca (AZ, NASDAQ: AZN) announced that baxdrostat has achieved both primary and secondary endpoints in the...
Eolas Therapeutics Gains Full Rights to AZD4041 for Opioid Use Disorder Development
US-based Eolas Therapeutics has entered into an agreement with its UK partner AstraZeneca (AZ, NASDAQ:...
JCR Pharmaceuticals Signs Licensing Agreement with AstraZeneca’s Alexion for JUST-AAV Gene Therapy Platform
Japan-based JCR Pharmaceuticals Co., Ltd. (TYO: 4552) announced a licensing agreement with UK-based AstraZeneca’s (NASDAQ:...
AstraZeneca in Talks for $15B Licensing Deal for Ivonescimab with Summit Therapeutics
UK-based AstraZeneca plc (AZ, NASDAQ: AZN) is reportedly in negotiations with Summit Therapeutics, the US...
AstraZeneca CEO Soriot Explores US Stock Listing Move, Potentially Impacting London Exchange
AstraZeneca (AZ, NASDAQ: AZN) CEO Pascal Soriot is exploring plans to move the British pharmaceutical...
HutchMed’s Orpathys Approved in China for EGFR-MET Co-Mutation NSCLC
HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that it has received marketing approval from...
AstraZeneca Restructures to Form Gastrointestinal Oncology Business Unit
UK major AstraZeneca (AZ, NASDAQ: AZN) this week reportedly unveiled a new organizational restructuring plan,...
FDA Approves AstraZeneca’s Datopotamab deruxtecan for EGFR-Mutated NSCLC
The US Food and Drug Administration (FDA) this week approved Datopotamab deruxtecan (Dato-DXd), a TROP-2-targeted...
Eccogene Announces First Patient Dosing in Phase Ib Study of AZD5004/ECC5004 in China
Sino-US firm Eccogene Inc., a partner of UK major AstraZeneca (AZ, NASDAQ: AZN), announced the...
Takeda’s Shan Guohong Departs to Join BeOne Medicines as Next Career Move
Shan Guohong, Global Senior Vice President of Takeda Pharmaceutical (TYO: 4502) and President of Takeda...
AstraZeneca’s Oncology Executive Michael Lai to Leave Company in June
Lai Minglong (Michael Lai), head of AstraZeneca’s (AZ, NASDAQ: AZN) global oncology business Dato-DXd and...
AstraZeneca and CSPC Pharma Collaborate on Novel Oral Drug Discovery
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) and China’s CSPC Pharmaceutical Group Ltd (HKG: 1093)...
AstraZeneca’s Calquence Combo Approved by EU for CLL Treatment
UK-based pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) announced that the European Commission (EC) has approved its...
AstraZeneca’s Imfinzi Approved for Limited Stage Small Cell Lung Cancer in China
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) received approval from China’s National Medical Products Administration...
Danaher Partners with AstraZeneca to Advance Precision Medicine
US-based science and tech services giant Danaher Corporation (NYSE: DHR) announced a strategic partnership with...
AstraZeneca’s Imfinzi Gets Positive Opinion for Bladder Cancer Perioperative Treatment
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) announced that the European Medicines Agency’s (EMA) Committee...